AstraZeneca Can't Take Diabetes Drug IP Appeal To Top Court
The U.K. Supreme Court has refused to consider AstraZeneca's last-ditch bid to revive patent protections for its billion-dollar diabetes drug dapagliflozin, as generic competition prepares to hit the market....To view the full article, register now.
Already a subscriber? Click here to view full article